FASENRA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Benralizumab.
Product ID | 0310-1730_220fd267-9bb7-49d6-a86f-a0fd6718ac46 |
NDC | 0310-1730 |
Product Type | Human Prescription Drug |
Proprietary Name | FASENRA |
Generic Name | Benralizumab |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2017-11-14 |
Marketing Category | BLA / BLA |
Application Number | BLA761070 |
Labeler Name | AstraZeneca Pharmaceuticals LP |
Substance Name | BENRALIZUMAB |
Active Ingredient Strength | 30 mg/mL |
Pharm Classes | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC],Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2017-11-14 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761070 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2017-11-14 |
Marketing Category | BLA |
Application Number | BLA761070 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-11-14 |
Ingredient | Strength |
---|---|
BENRALIZUMAB | 30 mg/mL |
SPL SET ID: | da6aca1a-19ed-44a4-abb7-696c7d58b784 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0310-1730 | FASENRA | Benralizumab |
0310-1830 | FASENRA | Benralizumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
FASENRA 98375565 not registered Live/Pending |
AstraZeneca AB 2024-01-25 |
FASENRA 87128498 5612391 Live/Registered |
AstraZeneca AB 2016-08-05 |